Skip to content

Introducing Electronic Alerts to Reduce Inappropriate Digoxin Prescribing in Older Adults

Introducing Electronic Alerts to Reduce Inappropriate Digoxin Prescribing in Older Adults

Status
Not yet recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07008144
Acronym
Aldigo
Enrollment
5954
Registered
2025-06-06
Start date
2025-12-31
Completion date
2026-11-30
Last updated
2025-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Digoxin Overdose, Drug-Related Side Effects and Adverse Reaction

Keywords

digoxin, deprescription, Beers, computerized alerts, geriatrics, Elderly Hospitalized Patients

Brief summary

The intervention consists of introducing computerized alerts into the electronic medical record of the CSAPG (MIRA software), which are triggered when a physician prescribes digoxin at a dose higher than the recommended amount (more than 0.125 mg/day). The main objective of this study is to evaluate the effectiveness of a visible computerized alert aimed at physicians responsible for hospitalized elderly patients who have been prescribed digoxin at a dose higher than 0.125 mg/day (the recommended dose), in reducing the number of patients receiving inappropriate digoxin doses.

Detailed description

Intervention This quasi-experimental pre-post intervention study evaluates the effectiveness of computerized alerts integrated into the CSAPG electronic health record system (MIRA software). These alerts are triggered when a physician prescribes digoxin at a dose higher than the recommended 0.125 mg/day for elderly patients. Study Objective The main goal is to assess whether these alerts reduce the number of elderly hospitalized patients receiving inappropriate digoxin dosages. Study Design and Duration The study will last 18 months in total, with a 12-month data collection period at each site (6 months before and 6 months after the intervention). Sample Size and Population To detect a 25% reduction in inappropriate digoxin prescriptions with 80% power and a 0.05 alpha risk, the study requires 2,977 patients in both the pre- and post-intervention groups. Inclusion criteria include hospitalized men and women aged 65 and older. No patient exclusions are anticipated. Statistical Analysis The primary analysis will compare the proportion of patients receiving digoxin doses above the recommended level before and after the intervention using the Chi-square test.

Interventions

OTHERDigoxin alarm

A computerized alert will be integrated into the CSAPG electronic health record system (MIRA software). These alerts will be triggered when a physician prescribes digoxin at a dose higher than the recommended 0.125 mg/day for elderly patients.

Sponsors

Consorci Sanitari de l'Alt Penedès i Garraf
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Men and women over 64 years of age. * Hospitalized in inpatient wards of the study centers during the study period.

Exclusion criteria

* Pacients under 64 years old * Patients without complete data available

Design outcomes

Primary

MeasureTime frameDescription
Proportion of elderly inpatients receiving inappropriate digoxin dosesFrom baseline to hospital discharge, as much 3 monthsProportion of patients aged 65 and older who are prescribed digoxin at a dose higher than 0.125 mg/day during hospitalization. The outcome compares this proportion between the pre-intervention and post-intervention periods to evaluate the effectiveness of a computerized alert integrated into the electronic medical record system (MIRA).

Countries

Spain

Contacts

Primary ContactBeatriz P Ortiz Naranjo
beatrizortiznaranjo@gmail.com+34606820268

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026